Obesity, Polycystic Ovary Syndrome
Conditions
Brief summary
Weight reduction is the most important treatment target when polycystic ovary syndrome (PCOS) is linked to obesity. Liraglutide (LIRA) in dose of 3 mg was recently approved as an anti-obesity drug. Metformin could enhance weight lowering potential of liraglutide. We investigates short term interventions with low dose liraglutide in combination with metformin and high dose liraglutide alone influence on significant weight reduction in obese women with PCOS.
Interventions
DRUGliraglutide
Sponsors
University Medical Centre Ljubljana
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* 18 years old to menopause * polycystic ovary syndrome (NICHD criteria) * BMI of 30 kg/m² or higher
Exclusion criteria
* type 1 or type 2 diabetes mellitus * history of carcinoma * Cushing's syndrome or congenital (non-classic) adrenal hyperplasia * personal or family history of MEN 2 * significant cardiovascular, kidney or hepatic disease * the use of medications known or suspected to affect reproductive or metabolic functions * the use of statins, within 90 days prior to study entry
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main outcome was change in body weight. | Patient's body weight was measured at the base point and after 12 weeks of clinical trial. |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome was change in body mass index (BMI) | Patient's body weight were measured at the base point and after 12 weeks of clinical trial. Patient's height was measured at the base point. |
Countries
Slovenia
Outcome results
None listed